Jefferies Financial Group Inc. Has $4.16 Million Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Key Points

• Jefferies Financial Group Inc. increased its holdings in Oruka Therapeutics by 15.7% during the first quarter, owning approximately 1.08% of the company with a total value of $4.16 million.
• Several hedge funds, including Wellington Management Group and Frazier Life Sciences Management, have also significantly increased their stakes in Oruka, indicating strong institutional interest.
• Wall Street analysts overwhelmingly rate Oruka Therapeutics as a buy, with an average target price of $40.38 per share.

Jefferies Financial Group Inc. increased its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 15.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 405,029 shares of the company's stock after acquiring an additional 55,000 shares during the period. Jefferies Financial Group Inc. owned about 1.08% of Oruka Therapeutics worth $4,156,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in Oruka Therapeutics during the fourth quarter worth $54,000. Cannon Global Investment Management LLC acquired a new position in shares of Oruka Therapeutics during the 1st quarter worth approximately $195,000. Squarepoint Ops LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at approximately $236,000. Jane Street Group LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $343,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Oruka Therapeutics in the 4th quarter worth $384,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ORKA has been the topic of a number of research reports. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Monday, July 21st. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Wednesday, July 23rd. Finally, BTIG Research initiated coverage on Oruka Therapeutics in a research report on Thursday, May 22nd. They issued a "buy" rating for the company. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $40.38.

Oruka Therapeutics Stock Performance

NASDAQ ORKA traded down $1.31 during mid-day trading on Wednesday, reaching $14.19. 171,178 shares of the stock were exchanged, compared to its average volume of 255,151. The business's fifty day simple moving average is $12.97 and its 200 day simple moving average is $11.42. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $52.32. The stock has a market capitalization of $531.27 million, a PE ratio of -3.15 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. On average, analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.